Advertisements



AbbVie: A Compelling Buy

AbbVie: A Compelling Buy.....»»

Category: topSource: seekingalphaDec 6th, 2018

AbbVie: Still A Compelling Buy?

AbbVie: Still A Compelling Buy?.....»»

Category: topSource: seekingalphaAug 27th, 2018

Schiff-ting The Goal Posts: House Intel Chairman Claims Trump-Russia Collusion "Compelling" But Not Necessarily "Criminal"

Schiff-ting The Goal Posts: House Intel Chairman Claims Trump-Russia Collusion "Compelling" But Not Necessarily "Criminal".....»»

Category: blogSource: zerohedgeFeb 17th, 2019

Bert"s Recent Purchase - AbbVie

Bert"s Recent Purchase - AbbVie.....»»

Category: topSource: seekingalphaFeb 17th, 2019

AbbVie Biotherapeutics director leads team against cancer

Looking back on her life, Diane Hollenbaugh isn’t exactly surprised she wound up discovering new ways to battle cancer. “I was always the one trying to figure out how things work and how to take things apart and put them back together,” said.....»»

Category: topSource: bizjournalsFeb 14th, 2019

AbbVie Is Too Risky Right Now

AbbVie Is Too Risky Right Now.....»»

Category: topSource: seekingalphaFeb 14th, 2019

BioArctic - Full Year Report January - December 2018

STOCKHOLM, Feb. 14, 2019 /PRNewswire/ -- BioArctic's partner Eisai will initiate BAN2401 confirmatory Phase 3-study in early Alzheimer's disease. AbbVie in-licensed the Parkinson po.....»»

Category: earningsSource: benzingaFeb 14th, 2019

With 2019 Rate Hike Chances Near Zero, Commodities Are Even More Compelling

With 2019 Rate Hike Chances Near Zero, Commodities Are Even More Compelling.....»»

Category: topSource: seekingalphaFeb 13th, 2019

Why The IoT ETF Matters

Some thematic exchange traded funds go overlooked despite offering investors exposure to compelling, fast-growing market niches. read more.....»»

Category: blogSource: benzingaFeb 12th, 2019

Becton, Dickinson Becomes #155 Most Shorted S&P 500 Component, Replacing AbbVie

Market News Video.....»»

Category: topSource: redinewsFeb 12th, 2019

Lions Gate: Disappointing Quarter, But Shares May Offer Compelling Risk/Reward

Lions Gate: Disappointing Quarter, But Shares May Offer Compelling Risk/Reward.....»»

Category: topSource: seekingalphaFeb 12th, 2019

Anadarko selloff brings "compelling entry point," says JPMorgan

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 12th, 2019

AbbVie Suffers Market Loss For Humira In Europe, But The U.S. Is A Different Story

AbbVie Suffers Market Loss For Humira In Europe, But The U.S. Is A Different Story.....»»

Category: topSource: seekingalphaFeb 11th, 2019

Cognex: Compelling Entry Point Ahead Of Earnings Announcement

Cognex: Compelling Entry Point Ahead Of Earnings Announcement.....»»

Category: topSource: seekingalphaFeb 11th, 2019

AbbVie, Teneobio enter global strategic transaction to develop TNB-383B

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 11th, 2019

63% Of A British Audience Would Prefer To Cut Ties With Saudi Arabia

Authored by Nasim Ahmed via MiddleEastMonitor.com, A night of compelling debate at the Emmanuel Centre.....»»

Category: blogSource: zerohedgeFeb 7th, 2019

Neurocrine expects $20M in revenue milestones under the AbbVie agreement in FY19

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 5th, 2019

Roth IRAs: What you need to know about conversions and “backdoor” contributions

The unique tax treatment of Roth IRAs presents a compelling opportunity for investors. Though income limits may prevent higher-earning individuals from making direct contributions to a Roth IRA, there are two other approaches that should be considered .....»»

Category: topSource: bizjournalsFeb 3rd, 2019

Verastem: A Compelling Risk/Reward Profile

Verastem: A Compelling Risk/Reward Profile.....»»

Category: topSource: seekingalphaFeb 1st, 2019

Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY

Pfizer (PFE), Allergan (AGN), AbbVie (ABBV) and Novartis (NVS) report Q4 results. Want the latest recommendations from Zacks Investment Research? Today, y.....»»

Category: smallbizSource: nytFeb 1st, 2019

Top Research Reports for Union Pacific, AbbVie & General Dynamics

Top Research Reports for Union Pacific, AbbVie & General Dynamics Thursday, January 31, 2019The Zacks Research Daily presents the best research out.....»»

Category: personnelSource: nytJan 31st, 2019